These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 19944196)

  • 1. Six months neoadjuvant imatinib improves resectability potential of gastric stromal tumors in Egyptian patients.
    Saied GM; Kensarah AM
    Int J Surg; 2010; 8(2):105-8. PubMed ID: 19944196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST).
    Fiore M; Palassini E; Fumagalli E; Pilotti S; Tamborini E; Stacchiotti S; Pennacchioli E; Casali PG; Gronchi A
    Eur J Surg Oncol; 2009 Jul; 35(7):739-45. PubMed ID: 19110398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations.
    Haller F; Detken S; Schulten HJ; Happel N; Gunawan B; Kuhlgatz J; Füzesi L
    Ann Surg Oncol; 2007 Feb; 14(2):526-32. PubMed ID: 17139461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs).
    Sym SJ; Ryu MH; Lee JL; Chang HM; Kim TW; Kim HC; Kim KH; Yook JH; Kim BS; Kang YK
    J Surg Oncol; 2008 Jul; 98(1):27-33. PubMed ID: 18452195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group.
    Blay JY; Le Cesne A; Ray-Coquard I; Bui B; Duffaud F; Delbaldo C; Adenis A; Viens P; Rios M; Bompas E; Cupissol D; Guillemet C; Kerbrat P; Fayette J; Chabaud S; Berthaud P; Perol D
    J Clin Oncol; 2007 Mar; 25(9):1107-13. PubMed ID: 17369574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Neoadjuvant therapy with imatinib mesilate for gastrointestinal stromal tumor of the stomach before subsequent successful surgical resection].
    Yamamoto K; Imamura H; Furukawa H; Kishimoto T; Miyazaki Y; Ohshiro R; Tatsuta M; Ohsato H; Fukunaga M; Nakayama T; Fujimi S; Takemoto H; Kondo M; Kamigaki S; Ohta K; Nakata Y
    Gan To Kagaku Ryoho; 2006 Nov; 33(12):1875-7. PubMed ID: 17212133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Gastrointestinal stromal tumour: our experience].
    Versaci A; Macrì A; Ieni A; Terranova M; Leonello G; Saladino E; Speciale G; Famulari C
    Chir Ital; 2009; 61(2):161-9. PubMed ID: 19536989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Laparoscopic resection of clinically suspected gastric stromal tumors.
    Berindoague R; Targarona EM; Feliu X; Artigas V; Balagué C; Aldeano A; Lahoud A; Navines J; Fernandez-Sallent E; Trias M
    Surg Innov; 2006 Dec; 13(4):231-7. PubMed ID: 17227921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors.
    Seshadri RA; Rajendranath R
    J Cancer Res Ther; 2009; 5(4):267-71. PubMed ID: 20160360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A study of the postoperative course in cases of GIST of the stomach. The efficacy of imatinib in cases of recurrence.
    Higashi D; Watanabe Y; Hirano K; Shimomura T; Egawa Y; Tomiyasu T; Ishibashi Y; Futami K; Maekawa T; Ota A; Oshige K; Iwashita A
    Anticancer Res; 2009 Nov; 29(11):4893-6. PubMed ID: 20032453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic analysis of patients with gastrointestinal stromal tumors: a single unit experience with surgical treatment of primary disease.
    Cao H; Zhang Y; Wang M; Shen DP; Sheng ZY; Ni XZ; Wu ZY; Liu Q; Shen YY; Song YY
    Chin Med J (Engl); 2010 Jan; 123(2):131-6. PubMed ID: 20137358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surgical treatment of locally advanced, non-metastatic, gastrointestinal stromal tumours after treatment with imatinib.
    Tielen R; Verhoef C; van Coevorden F; Gelderblom H; Sleijfer S; Hartgrink HH; Bonenkamp JJ; van der Graaf WT; de Wilt JH
    Eur J Surg Oncol; 2013 Feb; 39(2):150-5. PubMed ID: 23084087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy and safety of adjuvant post-surgical therapy with imatinib in gastrointestinal stromal tumor patients with high risk of recurrence: interim analysis from a multicenter prospective clinical trial].
    Zhan WH; Wang PZ; Shao YF; Wu XT; Gu J; Li R; Wan DS; Ding KF; Shi YQ; Yu JR; Lu HS; Zou XM; Bi JW; Sun YH; Lu YF; Chen DD; Zhang XH
    Zhonghua Wei Chang Wai Ke Za Zhi; 2006 Sep; 9(5):383-7. PubMed ID: 17043955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.
    Blanke CD; Rankin C; Demetri GD; Ryan CW; von Mehren M; Benjamin RS; Raymond AK; Bramwell VH; Baker LH; Maki RG; Tanaka M; Hecht JR; Heinrich MC; Fletcher CD; Crowley JJ; Borden EC
    J Clin Oncol; 2008 Feb; 26(4):626-32. PubMed ID: 18235122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multi-centre analysis of the impact of updated risk stratification on follow-up of gastric gastro-intestinal stromal tumours in the post-imatinib era.
    Reece-Smith AM; MacGoey P; Shah MA; Leeder P; Andrew DR; McCulloch T; Parsons SL
    Eur J Surg Oncol; 2012 Jun; 38(6):484-9. PubMed ID: 22342866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of neoadjuvant Imatinib therapy on outcome and survival after rectal gastrointestinal stromal tumour.
    Machlenkin S; Pinsk I; Tulchinsky H; Ziv Y; Sayfan J; Duek D; Rabau M; Walfisch S
    Colorectal Dis; 2011 Oct; 13(10):1110-5. PubMed ID: 21040362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate.
    Rutkowski P; Nowecki Z; Nyckowski P; Dziewirski W; Grzesiakowska U; Nasierowska-Guttmejer A; Krawczyk M; Ruka W
    J Surg Oncol; 2006 Mar; 93(4):304-11. PubMed ID: 16496358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gastrointestinal stromal tumors (GISTs) on prostate needle biopsy: A clinicopathologic study of 8 cases.
    Herawi M; Montgomery EA; Epstein JI
    Am J Surg Pathol; 2006 Nov; 30(11):1389-95. PubMed ID: 17063078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gastric GIST: a single institutional retrospective experience with surgical treatment for primary disease.
    An JY; Choi MG; Noh JH; Sohn TS; Kang WK; Park CK; Kim S
    Eur J Surg Oncol; 2007 Oct; 33(8):1030-5. PubMed ID: 17428635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A case of Giant GIST of the stomach successfully treated with imatinib mesylate neoadjuvant therapy and followed postoperatively].
    Okuda H; Tanaka H; Ueno M; Shitani M; Nasuno M; Suzuki C; Nishimura S; Kimura H; Yonezawa K; Abe T; Yoshida Y; Kawabata M
    Gan To Kagaku Ryoho; 2005 Nov; 32(12):1941-4. PubMed ID: 16282731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.